Company profilePharmaceutical#858 of 1,318 in Pakistan✓ No DRAP alerts

CCL Pharmaceuticals DSL: 05-354-0077-068122D

Pharmaceutical company · 8 brands · 11 molecules

8 registered products 11 pharmaceutical brands 11 distinct molecules 0 DRAP alerts

Company overview

8
registered products
11
pharmaceutical brands
11
distinct molecules
0
therapeutic classes
0
DRAP alerts

CCL Pharmaceuticals DSL: 05-354-0077-068122D is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 8 product registrations across 11 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by CCL

12 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

12
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202612

Top molecules by brand count

Carboplatin ...... 150 Mg1 brand
Carboplatin ...... 450 Mg1 brand
Tryhydrated Irinotecan Hci ...... 100 Mg1 brand
Oxaliplatin .... 50Mg1 brand
Oxaliplatin ...... 100 Mg1 brand
Irinotecan ...... 40 Mg1 brand
Etoposide ...... 100 Mg1 brand
Paclitaxel ...... 150 Mg1 brand
Paclitaxel ...... 30 Mg1 brand
Cisplatin ...... 50 Mg1 brand

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official12 products · Rs 809.54 – Rs 40,431.74
Median across source: Rs 6,159.22

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

AbirateroneAceclofenacBicalutamideBortezomibIrinotecan 20MgSevoflurane
Pharmasol (Pvt) Ltd. holds 110 molecules not in this portfolio
AcetazolamideAcyclovirAlpha KetoanaloguesAnastrazoleAnastrozoleAprepitant
Oncogen Pharma (Pvt) Limited holds 7 molecules not in this portfolio
AbirateroneCapecitabineDocetaxelImatinibLenalidomideNilotinib

Get the full profile for CCL

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.